WatsonPharmaceuticals, Inc. has resumed shipments to reintroduce its intravenousiron replacement therapy INFeD (iron dextran injection,USP). The product,which had been out of stock due to changes in the final product manufacturingsite and issues with raw material supply, is re-entering the market earlierthan expected. Watson expects to be in a normal supply situation for INFeDshortly. INFeD(R) is an iron dextran injection indicated for the treatment ofpatients with documented iron deficiency anemia in whom oral administration isunsatisfactory or impossible. INFeD was approved, and has been available forclinical use in the U.S since 1992.
